
Telmisartan (40mg) + Metoprolol Succinate (25mg)
Active composition
+1 more active ingredient
Telmisartan selectively blocks angiotensin II receptors, leading to vasodilation and decreased blood pressure.
Metoprolol Succinate blocks beta-1 adrenergic receptors, leading to decreased heart rate and contractility, thereby lowering blood pressure.
Medical applications
Inditel MX 40 mg/25 mg Tablet is a combination antihypertensive medication containing Telmisartan 40 mg and Metoprolol Succinate 25 mg. Telmisartan, an angiotensin II receptor blocker (ARB), functions by selectively inhibiting the binding of angiotensin II to the AT1 receptor, thereby promoting vasodilation and reducing aldosterone secretion, which leads to decreased blood pressure and reduced cardiovascular strain. Metoprolol Succinate, a cardioselective beta-1 adrenergic receptor blocker, decreases heart rate, myocardial contractility, and cardiac output, contributing to blood pressure reduction and improved cardiac efficiency. This combination is indicated for the management of essential hypertension, providing synergistic effects to achieve optimal blood pressure control and reduce the risk of cardiovascular events such as stroke, myocardial infarction, and heart failure. Inditel MX is particularly beneficial in patients requiring dual therapy or those with concomitant cardiac conditions where beta-blockade is advantageous. The extended-release formulation of Metoprolol Succinate ensures sustained therapeutic plasma levels, enhancing patient compliance and minimizing fluctuations in blood pressure. Therapy should be initiated under medical supervision with regular monitoring of blood pressure, renal function, and electrolyte levels to adjust dosing and detect potential adverse effects such as hypotension, bradycardia, or hyperkalemia. Inditel MX should be used cautiously in patients with hepatic or renal impairment and contraindicated in those with severe bradycardia, heart block, or hypersensitivity to its components.
Dosage information not available. Please consult your doctor or pharmacist.
Important precautions
Based on clinical trials and patient reports.
Overall Tolerance
Common Side Effects
Inditel MX 40 mg/25 mg Tablet is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.
High Risk
Inditel MX 40 mg/25 mg Tablet is probably safe to use during breastfeeding. Limited human data suggests that the drug does not represent any significant risk to the baby.
Medical Advice
Inditel MX 40 mg/25 mg Tablet is safe to use in patients with kidney disease. No dose adjustment of Inditel MX 40 mg/25 mg Tablet is recommended.
Exercise Caution
Inditel MX 40 mg/25 mg Tablet may decrease alertness, affect your vision or make you feel sleepy and dizzy. Do not drive if these symptoms occur.
Consult Doctor
Inditel MX 40 mg/25 mg Tablet should be used with caution in patients with liver disease. Dose adjustment of Inditel MX 40 mg/25 mg Tablet may be needed. Please consult your doctor.
Regular Checkup
0 reviews for Inditel MX 40 mg/25 mg Tablet

Telmisartan (40mg) + Metoprolol Succinate (25mg)
Cheaper alternative availability
This medicine doesn't have a cheaper alternative with the same composition. Our health advisors can help you find other savings options based on your prescription.
Active composition
+1 more active ingredient
Telmisartan selectively blocks angiotensin II receptors, leading to vasodilation and decreased blood pressure.
Metoprolol Succinate blocks beta-1 adrenergic receptors, leading to decreased heart rate and contractility, thereby lowering blood pressure.
Medical applications
Inditel MX 40 mg/25 mg Tablet is a combination antihypertensive medication containing Telmisartan 40 mg and Metoprolol Succinate 25 mg. Telmisartan, an angiotensin II receptor blocker (ARB), functions by selectively inhibiting the binding of angiotensin II to the AT1 receptor, thereby promoting vasodilation and reducing aldosterone secretion, which leads to decreased blood pressure and reduced cardiovascular strain. Metoprolol Succinate, a cardioselective beta-1 adrenergic receptor blocker, decreases heart rate, myocardial contractility, and cardiac output, contributing to blood pressure reduction and improved cardiac efficiency. This combination is indicated for the management of essential hypertension, providing synergistic effects to achieve optimal blood pressure control and reduce the risk of cardiovascular events such as stroke, myocardial infarction, and heart failure. Inditel MX is particularly beneficial in patients requiring dual therapy or those with concomitant cardiac conditions where beta-blockade is advantageous. The extended-release formulation of Metoprolol Succinate ensures sustained therapeutic plasma levels, enhancing patient compliance and minimizing fluctuations in blood pressure. Therapy should be initiated under medical supervision with regular monitoring of blood pressure, renal function, and electrolyte levels to adjust dosing and detect potential adverse effects such as hypotension, bradycardia, or hyperkalemia. Inditel MX should be used cautiously in patients with hepatic or renal impairment and contraindicated in those with severe bradycardia, heart block, or hypersensitivity to its components.
Dosage information not available. Please consult your doctor or pharmacist.
Important precautions
Based on clinical trials and patient reports.
Overall Tolerance
Common Side Effects
Inditel MX 40 mg/25 mg Tablet is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.
High Risk
Inditel MX 40 mg/25 mg Tablet is probably safe to use during breastfeeding. Limited human data suggests that the drug does not represent any significant risk to the baby.
Medical Advice
Inditel MX 40 mg/25 mg Tablet is safe to use in patients with kidney disease. No dose adjustment of Inditel MX 40 mg/25 mg Tablet is recommended.
Exercise Caution
Inditel MX 40 mg/25 mg Tablet may decrease alertness, affect your vision or make you feel sleepy and dizzy. Do not drive if these symptoms occur.
Consult Doctor
Inditel MX 40 mg/25 mg Tablet should be used with caution in patients with liver disease. Dose adjustment of Inditel MX 40 mg/25 mg Tablet may be needed. Please consult your doctor.
Regular Checkup
0 reviews for Inditel MX 40 mg/25 mg Tablet















